Clinical trial
Raltitrexed in Treating Children With Refractory Acute Leukemia
NCT00003528 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003528 |
|---|---|
| Title | Raltitrexed in Treating Children With Refractory Acute Leukemia |
| Official title | A Phase I Trial of Tomudex in Children With Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | raltitrexed |
| Enrollment | 30 |
| Start date | Sep 1, 1998 |
| Primary completion | Jun 1, 2002 |
| First posted | Mar 1, 2004 |
| Last update posted | Jan 16, 2013 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: